- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07449520
비만에 대한 내시경적 슬리브 위성형술(ESG) 전향적 임상시험(EGO-Trial)
비만 치료를 위한 내시경적 슬리브 위성형술(ESG) 전향적 임상시험
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
연구 개요
상세 설명
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Armelle TAKEDA
- 전화번호: 0033 390 413608
- 이메일: armelle.takeda@ihu-strasbourg.eu
연구 연락처 백업
- 이름: Clinical Research Team
- 이메일: rc-ihu@ihu-strasbourg.eu
연구 장소
-
-
-
Baie-Mahault, 과들루프
- 아직 모집하지 않음
- Clinique les Eaux Claires
-
연락하다:
- Venetia AVENDANO
- 전화번호: 0033 5 90 25 95 65
- 이메일: zulemacu@yahoo.com
-
-
-
-
-
Aix-en-Provence, 프랑스
- 모병
- Hôpital Privé de Provence
-
연락하다:
- Hugues SEBBAG
- 전화번호: 0033 4 42 21 12 11
- 이메일: hsebbag.ppr@hotmail.fr
-
Besançon, 프랑스
- 아직 모집하지 않음
- Polyclinique de Franche-Comté
-
연락하다:
- Henry-Alexis MERCOLI
- 전화번호: 0033 3 81 41 81 41
- 이메일: docteur.mercoli@gmail.com
-
Lille, 프랑스
- 아직 모집하지 않음
- Hôpital HURIEZ
-
연락하다:
- Robert CAIAZZO
- 전화번호: 0033 3 20 44 42 73
- 이메일: robert.caiazzo@univ-lille2.fr
-
Lyon, 프랑스
- 모병
- Clinique de la Sauvegarde
-
연락하다:
- Marie-Cécile BLANCHET
- 전화번호: +33 4 37 49 70 10
- 이메일: blanchet@chirurgien-digestif.com
-
Lyon, 프랑스
- 모병
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
연락하다:
- Maud ROBERT
- 전화번호: 0033 4 72 11 62 61
- 이메일: Maud.robert@chu-lyon.fr
-
Montpellier, 프랑스
- 아직 모집하지 않음
- Clinique Clémentville
-
연락하다:
- Marta SILVESTRI
- 전화번호: 0033 4 67 06 70 00
- 이메일: docteur.m.silvestri@gmail.com
-
Saint-Etienne, 프랑스
- 아직 모집하지 않음
- Centre Mutualiste de l'Obésité
-
연락하다:
- Pierre BLANC
- 전화번호: 0033 4 77 81 82 88
- 이메일: PBLANC@mutualite-loire.com
-
Saint-Grégoire, 프랑스
- 아직 모집하지 않음
- CHP Saint-Grégoire
-
연락하다:
- Adrien STERKERS
- 전화번호: +33 2 99 23 93 10
- 이메일: asterkers@vivalto-sante.com
-
Strasbourg, 프랑스
- 모병
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
연락하다:
- Silvana PERRETTA
- 전화번호: 0033 3 69 55 05 31
- 이메일: perretta@unistra.fr
-
Sète, 프랑스
- 모병
- Polyclinique Sainte Thérèse
-
연락하다:
- Thibaut COSTE
- 전화번호: 0033 4 67 18 88 20
- 이메일: thibautcoste@gmail.com
-
Échirolles, 프랑스
- 아직 모집하지 않음
- Clnique des Cèdres
-
연락하다:
- Fabien STENARD
- 전화번호: 0033 4 56 58 14 90
- 이메일: fabien.stenard@cliniquedescedres.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult patients with obesity scheduled for endoscopic gastroplasty
설명
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_ONLY
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
내시경 위성형술(ESG)을 예정한 모든 성인 비만 환자
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Total Body Weight Loss
기간: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Excess weight loss
기간: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
기간: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
기간: From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
기간: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
기간: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
기간: From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 25-004
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .